RecruitingPhase 2NCT06051240

Lithium Treatment to Prevent Cognitive Impairment After Brain Radiotherapy

Sponsor

Region Stockholm

Enrollment

84 participants

Start Date

Feb 16, 2024

Study Type

INTERVENTIONAL

Conditions

Radiotherapy Side Effect Cognitive Impairment Brain Tumor Radiotherapy; Complications Cognitive Decline Memory Impairment Late Effect of Radiation

Summary

Randomized, placebo-controlled, double-blinded, parallel group clinical trial to investigate if 6 months of oral lithium tablets (S-lithium 0,5-1,0 mmol/l) will prevent cognitive decline after brain radiotherapy in pediatric brain tumor survivors. Primary outcome measure is Processing Speed Index (PSI) 2 years after start of study treatment.

Eligibility

Min Age: 5 Years

Plain Language Summary

Simplified for easier understanding

This study tests whether the mood-stabilizing drug lithium can help protect the thinking and memory abilities of children who received brain radiation as part of cancer treatment. Radiation to the brain can cause long-term cognitive problems, and researchers hope lithium may help prevent or reduce this. **You may be eligible if...** - You (or your child) received radiation to the brain or spine for a brain tumor within the past 7 years - You were under 18 years old at the time of radiation and are now older than 5 - You use effective contraception if you could become pregnant **You may NOT be eligible if...** - You have an allergy to lithium - You have kidney disease, heart disease, or thyroid problems - You have severe electrolyte or fluid imbalances - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.